Abstract
The approximate representation of the active site of the type 3 isozyme of the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD3) has been derived from the consideration of the proposed mechanism for the reduction reaction. Using the transition-state (TS), the mode of action of a number of inhibitors has been rationalised.
Keywords: Type 3, Isozyme, 17β-Hydroxysteroid dehydrogenase, 17β-HSD3, Transition-state, Reduction reaction
Letters in Drug Design & Discovery
Title: The Derivation of a Potential Transition-State for the Reduction Reaction Catalysed by 17β -Hydroxysteroid Dehydrogenase Type 3 (17β -HSD) - An Approximate Representation of its Active Site for Use in Drug Design and Discovery
Volume: 4 Issue: 7
Author(s): Moniola S. Olusanjo and Sabbir Ahmed
Affiliation:
Keywords: Type 3, Isozyme, 17β-Hydroxysteroid dehydrogenase, 17β-HSD3, Transition-state, Reduction reaction
Abstract: The approximate representation of the active site of the type 3 isozyme of the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD3) has been derived from the consideration of the proposed mechanism for the reduction reaction. Using the transition-state (TS), the mode of action of a number of inhibitors has been rationalised.
Export Options
About this article
Cite this article as:
Olusanjo S. Moniola and Ahmed Sabbir, The Derivation of a Potential Transition-State for the Reduction Reaction Catalysed by 17β -Hydroxysteroid Dehydrogenase Type 3 (17β -HSD) - An Approximate Representation of its Active Site for Use in Drug Design and Discovery, Letters in Drug Design & Discovery 2007; 4 (7) . https://dx.doi.org/10.2174/157018007781788525
DOI https://dx.doi.org/10.2174/157018007781788525 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells
Current Pharmaceutical Design Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Deciphering the Systems Biology of mTOR Inhibition by Integrative Transcriptome Analysis
Current Pharmaceutical Design miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer
Drug Design Reviews - Online (Discontinued) Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Analysis of Microarray Gene Expression Data
Current Bioinformatics PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Breast Cancer: A Review of Risk Factors and New Insights into Treatment
Current Cancer Therapy Reviews